Abstract is: Osteoprotegerin (OPG), also known as osteoclastogenesis inhibitory factor (OCIF) or tumour necrosis factor receptor superfamily member 11B (TNFRSF11B), is a cytokine receptor of the tumour necrosis factor (TNF) receptor superfamily encoded by the TNFRSF11B gene. OPG was first discovered as a novel secreted TNFR related protein that played a role in the regulation of bone density and later for its role as a decoy receptor for receptor activator of nuclear factor kappa-B ligand (RANKL). OPG also binds to TNF-related apoptosis-inducing ligand (TRAIL) and inhibits TRAIL induced apoptosis of specific cells, including tumour cells. Other OPG ligands include syndecan-1, glycosaminoglycans, von Willebrand factor, and factor VIII-von Willebrand factor complex. OPG has been identified as having a role in tumour growth and metastasis, heart disease, immune system development and signalling, mental health, diabetes, and the prevention of pre-eclampsia and osteoporosis during pregnancy.
Abstract is: Receptor activator of nuclear factor kappa-Β ligand (RANKL), also known as tumor necrosis factor ligand superfamily member 11 (TNFSF11), TNF-related activation-induced cytokine (TRANCE), osteoprotegerin ligand (OPGL), and osteoclast differentiation factor (ODF), is a protein that in humans is encoded by the TNFSF11 gene. RANKL is known as a type II membrane protein and is a member of the tumor necrosis factor (TNF) superfamily. RANKL has been identified to affect the immune system and control bone regeneration and remodeling. RANKL is an apoptosis regulator gene, a binding partner of osteoprotegerin (OPG), a ligand for the receptor RANK and controls cell proliferation by modifying protein levels of Id4, Id2 and cyclin D1. RANKL is expressed in several tissues and organs including: skeletal muscle, thymus, liver, colon, small intestine, adrenal gland, osteoblast, mammary gland epithelial cells, prostate and pancreas. Variation in concentration levels of RANKL throughout several organs reconfirms the importance of RANKL in tissue growth (particularly bone growth) and immune functions within the body.
| protein | Q8054 |
| P682 | biological process | ossification | Q1121544 |
| immune response | Q1612119 | ||
| response to lipopolysaccharide | Q14330834 | ||
| positive regulation of JUN kinase activity | Q14897628 | ||
| lymph node development | Q14897629 | ||
| circadian temperature homeostasis | Q14897630 | ||
| positive regulation of fever generation by positive regulation of prostaglandin secretion | Q14897631 | ||
| TNFSF11-mediated signaling pathway | Q14897632 | ||
| positive regulation of ERK1 and ERK2 cascade via TNFSF11-mediated signaling | Q14897633 | ||
| multinuclear osteoclast differentiation | Q21130978 | ||
| response to tumor necrosis factor | Q14599713 | ||
| regulation of apoptotic process | Q14633911 | ||
| multicellular organism development | Q14645705 | ||
| positive regulation of NF-kappaB transcription factor activity | Q14761969 | ||
| regulation of cell population proliferation | Q14818120 | ||
| response to interleukin-1 | Q14852023 | ||
| response to cytokine | Q14860535 | ||
| osteoclast differentiation | Q14860557 | ||
| positive regulation of bone resorption | Q14860560 | ||
| response to radiation | Q14863387 | ||
| tumor necrosis factor-mediated signaling pathway | Q14864211 | ||
| positive regulation of DNA-binding transcription factor activity | Q14864461 | ||
| mammary gland alveolus development | Q14864690 | ||
| apoptotic signaling pathway | Q14866112 | ||
| adaptive immune response | Q14887714 | ||
| P681 | cell component | plasma membrane | Q29548 |
| cell surface | Q189094 | ||
| cytosol | Q220599 | ||
| integral component of membrane | Q14327652 | ||
| membrane | Q14349455 | ||
| external side of plasma membrane | Q14633850 | ||
| integral component of plasma membrane | Q14859540 | ||
| P702 | encoded by | Tnfrsf11a | Q14900986 |
| P703 | found in taxon | house mouse | Q83310 |
| P527 | has part(s) | TNFR/NGFR cysteine-rich region | Q24780037 |
| Tumor necrosis factor receptor 11A, N-terminal | Q27830574 | ||
| P680 | molecular function | protein binding | Q167149 |
| metal ion binding | Q13667380 | ||
| transmembrane signaling receptor activity | Q14864356 | ||
| cytokine binding | Q14874270 | ||
| tumor necrosis factor-activated receptor activity | Q14877365 | ||
| P361 | part of | membrane protein | Q423042 |
| Tumour necrosis factor receptor 11A | Q24740580 | ||
| TNFR/NGFR cysteine-rich region, protein family | Q83147282 | ||
| Tumor necrosis factor receptor 11A, N-terminal domain, protein family | Q83167096 |
| Q24675157 | A novel member of the leukocyte receptor complex regulates osteoclast differentiation |
| Q28245637 | Anti-IL-20 monoclonal antibody inhibits the differentiation of osteoclasts and protects against osteoporotic bone loss |
| Q24321735 | Central control of fever and female body temperature by RANKL/RANK |
| Q24598872 | RANK is essential for osteoclast and lymph node development |
| Q27674275 | RANKL Employs Distinct Binding Modes to Engage RANK and the Osteoprotegerin Decoy Receptor |
| Q27665673 | Structure-based development of a receptor activator of nuclear factor- B ligand (RANKL) inhibitor peptide and molecular basis for osteopetrosis |
| Q28142247 | The osteoclast differentiation factor osteoprotegerin-ligand is essential for mammary gland development |
| Q24653311 | Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand |
| Q14900986 | Tnfrsf11a | encodes | P688 |
Search more.